Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Part of paid clinical trials in Glendora, California.
- Sponsor
- Immunovant Sciences GmbH
- Study ID
- NCT05517447
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Thyroid Eye Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Observational cohort study — OTHERObservational cohort study
- Batoclimab — DRUGBatoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study Details
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
Key Dates
- Start date
- Nov 6, 2022
- Status verified
- Apr 2026
- Primary completion
- Apr 2, 2026
- Completion
- Apr 2, 2026
Study Design
- Enrollment
- 109 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Other: Observational cohortProptosis responders in feeder studies will enter in a non-treatment observational study
- Experimental: Treatment CohortProptosis non-responders in feeder studies will be administered batoclimab of 680 milligram (mg) subcutaneous (SC) for 12 weeks followed by 340 mg SC for 12 weeks
Primary Outcome Measure
Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studies [ Time Frame: Up to Week 24 ]
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site Number - 1520 | Glendora | California | 91741 | - |
| Site Number - 1501 | Aurora | Colorado | 80045 | - |
| Site Number - 1526 | Livonia | Michigan | 48152 | - |
| Site Number - 1513 | Rochester | Minnesota | 55905 | - |
| Site Number - 1540 | Las Vegas | Nevada | 89184 | - |
| Site Number - 1508 | Houston | Texas | 77030 | - |
| Site Number - 1558 | Mesquite | Texas | 75149 | - |
| Site Number - 1511 | Morgantown | West Virginia | 26506 | - |
| Site Number - 1518 | Milwaukee | Wisconsin | 53226 | - |
Related coverage on Hipa.ai
- Batoclimab Phase 3 Thyroid Eye Disease Extension Study Completes Primary PhaseBatoclimab · Apr 2, 2026 · ClinicalTrials.gov
Find similar trials in Glendora, CA
Related Studies
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)PHASE2/PHASE3 · Recruiting · Sling Therapeutics, Inc. · Miami, Florida
- A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseasePHASE1/PHASE2 · Recruiting · Amgen · Little Rock, Arkansas
- Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)Not Yet Recruiting · THYROSCOPE INC. · San Jose, California
- The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid DysfunctionRecruiting · Walter Reed National Military Medical Center · Bethesda, Maryland